Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

54 results about "Anti cholinergic" patented technology

Anticholinergics are medications that are administered to lessen the nervous system's stimulation of smooth muscle tissue. An anticholinergic works by inhibiting the action of acetylcholine, the neurotransmitter responsible for signaling nerve activity.

Anticholinergic powder formulations for inhalation

An inhalable powder comprising:(a) an active substance consisting essentially of a compound of formula 1 wherein X− is a pharmaceutically acceptable anion; and(b) a physiologically acceptable excipient having an average particle size of 10 μm to 50 μm,processes for preparing the inhalable powder, and methods of administration for the treatment of respiratory complaints, particularly for the treatment of chronic obstructive pulmonary disease (COPD) and asthma.
Owner:BOEHRINGER INGELHEIM INT GMBH

New uses for quaternary ammonium anticholinergic muscarinic receptor antagonists in patients being treated for cognitive impairment or acute delirium

ActiveUS20080114014A1Maximizing beneficial effectMaximize the effectBiocideNervous disorderSolubilityFecal incontinence
A method for treating the adverse effects of acetyl-cholinesterase inhibitors used in the treatment of cognitive disorders such as acute delirium and cognitive impairment in elderly human patients. The administration of a clinically effective amount of a quaternary ammonium anti-cholinergic muscarinic receptor antagonist having very low lipid solubility substantially eliminates the adverse effects of urinary and / or fecal incontinence, nausea, bradycardia, bronchorrhea or brochospasm caused by the acetyl-cholinesterase inhibitors, without affecting the beneficial activity of the acetyl-cholinesterase inhibitors. This permits the administration of the optimum effective dosing of acetyl-cholinesterase inhibitors to provide maximum benefit to the patient with the added benefit of reducing or eliminating the unwanted side effects of fecal and urinary incontinence. Further, the combination of rivastigmine and glycopyrrolate has been effective in significantly improving cognitive function in patients suffering from acute dementia or cognitive impairment.
Owner:QAAM PHARMA LLC

Compositions and methods for bowel care in individuals with chronic intestinal pseudo-obstruction

ActiveUS7635709B2Shorten the construction periodDifficult to administerBiocideAmine active ingredientsBowel careSide effect
The present disclosure provides compositions and methods for on-going bowel care for persons with chronic intestinal pseudo-obstruction. The compositions and methods can be administered in a non-clinical setting. The compositions comprise acetylcholinesterase inhibitors for stimulating motility of the bowel in combination with anti-cholinergic agents to counteract the potentially dangerous cardiac side effects of the acetylcholinesterase inhibitor. In some examples, the acetylcholinesterase inhibitor, neostigmine, and the anti-cholinergic agent, glycopyrrolate, are combined in a pharmaceutical composition. Certain examples also provide the frequency and duration of administration of the disclosed drug combinations.
Owner:U S GOVERNMENT REPRESENTED BY THE DEPT OF VETERANS AFFAIRS

Transdermal compositions for Anti-cholinergic agents

InactiveUS20140037713A1Reduce morbidityAvoids undesirable odor and irritation effectsCosmetic preparationsOrganic active ingredientsOxybutyninSide effect
The present invention relates generally to compositions or formulations for transdermal or transmucosal administration of anti-cholinergic agents such as oxybutynin. The invention utilizes a novel delivery vehicle and is a substantially malodorous-free and irritation free transdermal formulation which is substantially live of long chain fatty alcohols, long-chain fatty acids, and long-chain fatty esters. A method is disclosed for treating a subject for hyperhidrosis with these formulations while reducing the incidences of peak concentrations of drug and undesirable side effects associated with oral anti-cholinergics.
Owner:ANTARES PHARMA IPL

Urological medical devices for release of prostatically beneficial therapeutic agents

According to an aspect of the invention, urological medical devices are provided, which comprise a prostatically beneficial agent selected from alpha-adrenergic blockers, antispasmodic agents, anticholinergic / antimuscarinic agents, calcium channel blockers, anti-inflammatory agents, hormone-affecting agents, anti-cancer agents, and combinations thereof, among others. The urological medical devices are adapted for implantation or insertion into a subject's urinary tract, whereupon at least a portion of the prostatically beneficial agent is released into the subject's prostatic urethra. The release profile of the prostatically beneficial agent is effective to treat a prostatic disorder, for example, benign prostate hypertrophy, prostate cancer or prostatitis, among others. Other aspects of the invention are directed to treating prostatic disorders.
Owner:BOSTON SCI SCIMED INC

Combination of a PDE4 inhibitor and tiotropium or derivative thereof for treating obstructive airways and other inflammatory diseases

The present invention relates to a combination of therapeutic agents useful in the treatment of obstructive airways and other inflammatory diseases comprising (I) a PDEIV inhibitor that is therapeutically effective in the treatment of said diseases when administered by inhalation; together with (II) an anti-cholinergic agent comprising a member selected from the group consisting of tiotropium and derivatives thereof that is therapeutically effective in the treatment of said diseases when administered by inhalation; as well as to a method of treating said obstructive airways and other inflammatory diseases comprising administering to said mammal by inhalation a therapeutically effective amount of said combination of therapeutic agents; and a pharmaceutical composition comprising a pharmaceutically acceptable carrier together with said combination of therapeutic agents; and a package containing a pharmaceutical composition for insertion into a device capable of simultaneous or sequential delivery of said pharmaceutical composition in the form of an aerosol or dry powder dispersion to said mammal, where said device is a metered dose inhaler or a dry powder inhaler. It is preferred that said anti-cholinergic agent component be tiotropium bromide.
Owner:BOEHRINGER INGELHEIM PHARM KG

Transdermal compositions for anticholinergic agents

InactiveUS20100216880A1Avoiding undesirable peak in drug concentrationReduce morbidityAntibacterial agentsBiocideOxybutyninLong chain fatty acid
The present invention relates generally to compositions or formulations for transdermal or transmucosal administration of anticholinergic agents such as oxybutynin. The invention utilizes a novel delivery vehicle and is a substantially malodorous-free and irritation free transdermal formulation which is substantially free of long chain fatty alcohols, long-chain fatty acids, and long-chain fatty esters. A method is disclosed for treating a subject for urinary incontinence with these formulations while reducing the incidences of peak concentrations of drug and undesirable side effects associated with oral anticholinergics.
Owner:ANTARES PHARMA IPL

Use of autonomic nervous system neurotransmitters inhibition and atrial parasympathetic fibers ablation for the treatment of atrial arrhythmias and to preserve drug effects

InactiveUSRE42961E1Increased occurrence of initiation of atrial flutterShorten the construction periodDiagnosticsHeart defibrillatorsNervous systemRight atrium
Atrial arrhythmias, a major contributor to cardiovascular morbidity, are believed to be influenced by autonomic nervous system tone. The main purpose of this invention was to highlight new findings that have emerged in the study of effects of autonomic nervous system tone on atrial arrhythmias, and its interaction with class III antiarrhythmic drug effects. This invention evaluates the significance of sympathetic and parasympathetic activation by determining the effects of autonomic nervous system using a vagal and stellar ganglions stimulation, and by using autonomic nervous system neurotransmitters infusion (norepinephrine, acetylcholine). This invention evaluates the autonomic nervous system effects on the atrial effective refractory period duration and dispersion, atrial conduction velocity, atrial wavelength duration, excitable gap duration during a stable circuit (such atrial flutter circuit around an anatomical obstacle), and on the susceptibility of occurrence (initiation, maintenance and termination) of atrial re-entrant arrhythmias in canine. This invention also evaluates whether autonomic nervous system activation effects via a local neurotransimitters infusion into the right atria can alter those of class III antiarrhythmic drug, sotalol, during a sustained right atrial flutter. This invention represents an emergent need to set-up and develop a new class of anti-cholinergic drug therapy for the treatment of atrial arrhythmias and to combine this new anti-cholinergic class to antiarrhythmic drugs. Furthermore, this invention also highlights the importance of a local application of parasympathetic neurotransmitters / blockers and a catheter ablation of the area of right atrium with the highest density of parasympathetic fibers innervation. This may significantly reduce the occurrence of atrial arrhythmias and may preserve the antiarrhythmic effects of any drugs used for the treatment of atrial re-entrant arrhythmias.
Owner:ST JUDE MEDICAL ATRIAL FIBRILLATION DIV

Combined Acetylcholinesterase Inhibitor and Quaternary Ammonium Antimuscarinic Therapy to Alter Progression of Cognitive Diseases

ActiveUS20130172398A1Prevents or substantially ameliorates the undesired side effects of acetyl-cholinesteraseMaximize the effectBiocideAmine active ingredientsDementia with Lewy bodiesPsychiatry
A method administers quaternary ammonium anti-cholinergic muscarinic receptor antagonists in combination with acetyl-cholinesterase inhibitors to treat either cognitive impairment or acute delirium. This therapy results in a modification of a cognitive disorder or disease, namely a slow down in the disease progression. In one preferred embodiment, the disease is dementia with Lewy Bodies. New formulations for quaternary ammonium anti-cholinergic muscarinic receptor antagonists are also disclosed.
Owner:QAAM PHARMA LLC

Crystalline anti-cholinergic tiotropium crystal

ActiveCN1634921ANo significant difference in formulation qualityOrganic active ingredientsOrganic chemistryAnticholinergic agentsTiotropium bromide
The invention relates to crystal unhydrous (1R,2R,4S,5S,7S)-7-[2-hydroxy-2,2-bis(2-thienyl) acetoxy]-9,9-dimethyl-3-oxa-9-azo cation tricyclo octane [3.3.1.02.4] nonane bromide, clinic use of tiotropium bromide anhydrous crystal as anti-cholinergic medicines, and preparation process of tiotropium bromide anhydrous crystal.
Owner:CHIA TAI TIANQING PHARMA GRP CO LTD

Methods And Compositions For Decreasing Saliva Production

ActiveUS20080102102A1Decrease saliva productionControl halitosisBiocideDigestive systemSialorrheaAnti cholinergic
The invention provides methods and compositions comprising an anti-cholinergic agent for decreasing saliva production and treating sialorrhea.
Owner:NEUROHEALING PHARMA INC

Combined Acetylcholinesterase Inhibitor and Quaternary Ammonium Antimuscarinic Therapy to Alter Progression of Cognitive Diseases

ActiveUS20130172379A1Prevents or substantially ameliorates the undesired side effects of acetyl-cholinesteraseMaximize the effectBiocideOrganic chemistryDementia with Lewy bodiesPsychiatry
A method administers quaternary ammonium anti-cholinergic muscarinic receptor antagonists in combination with acetyl-cholinesterase inhibitors to treat either cognitive impairment or acute delirium. This therapy results in a modification of a cognitive disorder or disease, namely a slow down in the disease progression. In one preferred embodiment, the disease is dementia with Lewy Bodies. New formulations for quaternary ammonium anti-cholinergic muscarinic receptor antagonists are also disclosed.
Owner:QAAM PHARMA LLC

Compositions and Methods for Treating Social Anxiety

InactiveUS20110218215A1Preventing social phobiaStop formationBiocideNervous disorderAtropine sulfateMedicine
The disclosure provides a pharmaceutical composition for treating social anxiety, performance anxiety, and social phobia comprising a therapeutic amount for die treatment of a patient of a β-adrenergic receptor antagonist, an anti-diarrheal compound, and an optional anticholinergic compound. The β-adrenergic receptor antagonist may be the lipophilic β-blocker propranolol HCl, the anti-diarrheal compound may be the opioid diphenoxylate HCl, and the optional anticholinergic compound may be atropine sulfate. The composition for treating performance anxiety and social phobia can further include a pharmaceutically acceptable carrier. A method of preventing or treating social anxiety, performance anxiety, and social phobia in a patient is also provided, comprising administering a composition of the disclosure to a patient in need of such treatment. The composition administered in the present method comprises a therapeutic amount of a β-adrenergic receptor antagonist, an anti-diarrheal compound, and an optional anticholinergic compound.
Owner:HOLLY BENJAMIN D

Method and composition for treating alzheimer-type dementia

There is described a method for increasing the maximal tolerated dose and thus the efficacy of an acetylcholinesterase inhibitor (AChEI) in a patient suffering from an Alzheimer type dementia by decreasing concomitant adverse effects by administration of said AChEI in combination with a non-anticholinergic antiemetic agent, whereby an enhanced acetylcholinesterase inhibition in the CNS of said patient is achieved and alleviation of the symptoms of Alzheimer type dementia in said patient is thereby improved to a greater extent. The use of a non-anticholinergic antiemetic agent for the preparation of a pharmaceutical composition for the treatment of Alzheimer type dementia in combination with an acetylcholinesterase inhibitor (AChEI) and pharmaceutical compositions comprising (a) a 5HT3 receptor antagonist, a dopamine antagonist, a H1-receptor antagonist, a cannabinoid agonist, aprepitant or casopitant as an antiemetic agent and (b) an acetylcholinesterase inhibitor are also described.
Owner:CHASE PHARMA CORP

Medicine for treating post stroke depression and application thereof

The invention relates to a medicine for treating post stroke depression and an application thereof. The medicine is prepared from the following medicinal raw materials in parts by weight: 25-35 parts of salvia miltiorrhiza, 25-35 parts of rhizoma acori graminei, 10-20 parts of ligusticum wallichii, 10-20 parts of radix paeoniae alba, 10-20 parts of polygala tenuifolia, 5-15 parts of safflower carthamus, 5-15 parts of peach kernel, 7-17 parts of prepared rhizoma cyperi, 5-15 parts of radix bupleuri, 5-15 parts of fructus aurantii, 5-15 parts of radix curcumae, 4-8 parts of pericarpium citri reticulatae viride, 10-20 parts of endothelium corneum gigeriae galli, 25-35 parts of fructus cannabis, 25-35 parts of spina date seed and 25-35 parts of tuber fleeceflower stem. The invention further relates to a composition containing the medicine and fluoxetine hydrochloride. The medicine combined with antidepressant is capable of accelerating the drug effect taking speed, the dose can be controlled, the course of treatment can be shortened, the 'contradictory phenomena' and 'anticholinergic side effect' can be reduced, the effect of the medicine by combining comprehensive rehabilitation therapy is relatively remarkable in the treatment process, and the medicine is capable of gradually replacing the antidepressant in the later period of treatment.
Owner:上海市闸北区中医医院

Permeation enhancing compositions for anticholinergic agents

InactiveUS20080260842A1Avoiding undesirable peak in drug concentrationReduce morbidityBiocideAerosol deliveryOxybutyninAnticholinergic agents
A transdermal or topical skin-friendly composition including anticholinergic agents, such as oxybutynin, a urea-containing compound and a carrier system. A method is disclosed for treating a subject for urinary incontinence while reducing the incidences of peak concentrations of drug and undesirable side effects associated with oral anticholinergics.
Owner:ANTARES PHARMA IPL

Combination of adrenergic agonist and tricyclo-alkylamine for relieving chronic pain without adverse side effects

This invention discloses that a combination of two drugs, from two different and previously unrelated categories, provides effective and long-lasting relief from neuropathic pain. Both drugs can be taken orally, in a convenient, painless, non-invasive manner that does not require injections. One drug in this combination is an alpha2 adrenergic agonist, exemplified by clonidine. The other drug in the pain-relieving combination has a tri-cyclo-alkyl-amine (TCAA) structure. At least some TCAA drugs have antagonist (receptor-blocking) activity at two entirely different classes of neuronal receptors: the muscarinic subclass of acetylcholine (ACh) receptors, and the NMDA subclass of glutamate receptors. Such drugs include ethopropazine, normally used as an anti-cholinergic drug, and desipramine, normally used as an anti-depressant. Tests by the Applicants have shown that at least some TCAA drugs can relieve neuropathic pain to a limited extent, but at the doses required to relieve pain, they cause adverse side effects, and any pain relief is relatively brief and short-lived. However, when a TCAA drug such as ethopropazine is administered together with an alpha2 adrenergic agonist such as clonidine, these drugs mutually potentiate one another's neuropathic pain-relieving action, and provide potent and sustained neuropathic pain relief, even when each agent is administered at a low dosage that is below its threshold for causing adverse side effects. Accordingly, this drug combination can provide safe and effective relief of neuropathic pain and possibly other types of chronic and / or intractable pain, at dosages which are so low that they do not pose serious risks of adverse side effects.
Owner:OLNEY JOHN W +2

Process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic

Dry powder formulations for inhalation containing a combination of an anti-cholinergic, a long-acting beta2-adrenoceptor agonist, and a corticosteroid are useful for the prevention and / or treatment of an inflammatory and / or obstructive airways disease.
Owner:CHIESI FARM SPA

Oligomer-Anticholinergic Agent Conjugates

The invention provides anticholinergic agents that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different as compared to the characteristics of the anticholinergic agent not attached to the water-soluble oligomer.
Owner:NEKTAR THERAPEUTICS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products